PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
 PolyPid (PYPD) Q2 2026 Earnings Call Transcript FDA accepts D-PLEX100 application with Priority Review, setting November approval target. | ||
Older | ||
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... PolyPid secures FDA Priority Review for D-Plex 100 and a $30 million upfront partnership with Azurity, positioning the company for a potential early 2027 commercial launch. | ||
 PolyPid Ltd. Q2 2026 Earnings Call Summary Moby summary of PolyPid Ltd.'s Q2 2026 earnings call | ||
 PolyPid Q2 Earnings Call Highlights PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada. D-PLEX100 is being developed to prevent surgical site infections in p | ||
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges PolyPid Ltd (PYPD) progresses with NDA submission and strategic partnerships, despite reporting a net loss and decreased cash reserves. | ||
 PolyPid Ltd. Q1 2026 Earnings Call Summary Moby summary of PolyPid Ltd.'s Q1 2026 earnings call | ||
 PolyPid (PYPD) Q1 2026 Earnings Transcript Yehuda Leibler: Thank you, operator, and thank you all for joining PolyPid's First Quarter 2026 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid. | ||
 PolyPid Q1 Earnings Call Highlights PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief Executive Officer Di | ||
 PolyPid Q1 2026 Earnings Call: Complete Transcript PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://edge.media-server.com/mmc/p/w3mvdb4o/ Summary PolyPid reported a net loss of $7.7 million for Q1 2026, an improvement from a loss of $8.3 million in Q1 2025, with operating expenses showing a | ||
 When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? We feel now is a pretty good time to analyse PolyPid Ltd.'s ( NASDAQ:PYPD ) business as it appears the company may be... | ||